CTOs on the Move


 
BioTime is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. BioTime`s pipeline is based on two platform technologies which encompass cell replacement and cell/drug delivery. BioTime`s lead cell replacement product candidate is OpRegen®, a retinal pigment epithelium transplant therapy in Phase 2 development for the treatment of dry age-related macular degeneration, the leading cause of blindness in the developed world. BioTime common stock is traded on the NYSE American and TASE under the symbol BTX.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.biotimeinc.com
  • 1010 Atlantic Avenue Suite 102
    Alameda, CA USA 94501
  • Phone: 510.521.3390

Executives

Name Title Contact Details

Similar Companies

Capstan Therapeutics

Capstan Therapeutics is a biotechnology company dedicated to advancing in vivo cell reprogramming. The core platform technology comprises proprietary targeted lipid nanoparticles conjugated with a recombinant protein binder such as monoclonal antibodies (tLNPs) designed to deliver payloads, including mRNA or gene editing tools, that can reprogram specific cell types in vivo. The platform technology has the potential to generate transformative therapies with applications across a broad range of disease areas, including oncology, autoimmune disorders, fibrosis, and monogenic blood disorders.

VGXI

VGXI is a Spring, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Woodside Senior Communities

Woodside Senior Communities is a Green Bay, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kosan Biosciences

Kosan Biosciences Incorporated is a Hayward, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pneuma Respiratory

Founded in 2015, Pneuma Respiratory is focused on creating therapeutic treatments for diseases of the lungs using a digital first platform for inhaled drug delivery. Our focus is to improve the potential effectiveness of currently available and novel drugs, with the initial targets being approved therapeutics for asthma and COPD. Pneuma is leveraging more than three decades of healthcare research and product development experience along with hand held device design and manufacturing expertise.